BeiGene
BGNE
#1092
Rank
$16.96 B
Marketcap
$156.39
Share price
0.84%
Change (1 day)
-28.90%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$16.64

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$16.64. In 2022 the company made an earnings per share (EPS) of -$19.37 a decrease over its 2021 EPS that were of -$15.21.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$16.64-14.09%
2022-$19.3727.35%
2021-$15.21-19.96%
2020-$19.0020.81%
2019-$15.7331.52%
2018-$11.96417.57%
2017-$2.31-37.16%
2016-$3.68158.95%
2015-$1.42

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$0.27-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.00-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA